FragScan: A Quantitative Fragment Scanning Strategy for Rational Drug Discovery

Area of Science:

• Computational chemistry
• Molecular modeling
• Drug discovery

Background:

• Calculating binding free energy is crucial but challenging in drug discovery.
• Traditional methods face limitations in balancing computational efficiency and accuracy.
• Existing methods struggle to quantitatively analyze individual ligand fragment contributions to binding affinity.

Purpose of the Study:

• Introduce a novel fragment scanning approach, FragScan, to address limitations in binding free energy calculations.
• Enable targeted analysis of fragment-receptor interactions by fragmenting ligands at rotatable bonds.
• Quantify the binding contribution of each ligand fragment accurately.

Main Methods:

• Developed FragScan, a fragment scanning approach that fragments ligand molecules at rotatable bonds.
• Decomposed ligands into structurally independent fragments to reduce computational complexity.
• Validated the method's performance in balancing efficiency and precision for energy calculations.

Main Results:

• FragScan effectively reduces computational complexity while maintaining high accuracy in binding energy calculations.
• The method accurately quantifies the binding contribution of individual ligand fragments.
• Demonstrated a quantitatively reliable framework for predicting ligand fragment-receptor interactions.

Conclusions:

• FragScan offers a valuable tool for decoding structure-activity relationships at the fragment level.
• The framework has significant potential for advancing rational drug design, including scaffold hopping and pharmacophore replacement.
• Expected to drive progress in the development of novel and potent therapeutic agents.